Neuromuscular

Presented at the 2025 PNS Annual Meeting, phase 2 ARDA data showed empasiprubart reduced IVIg retreatment risk and improved grip strength in patients with MMN.

New data from a phase 2 study presented at the 2025 PNS Annual Meeting showed that riliprubart reduced plasma NfL levels in CIDP, with greater reductions linked to stronger functional improvements.

Patients with Guillain-Barré syndrome treated with tanruprubart, formerly known as ANX005, reported significant benefits in mobility, self-care, and usual activity compared with placebo.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the Peripheral Nerve Society Annual Meeting.

A groundbreaking CRISPR therapy shows promise in treating hereditary ATTR amyloidosis, achieving significant serum TTR reductions and stable patient outcomes.

A pair of committee chairs for the Peripheral Nerve Society’s Annual Meeting shared key sessions and trends clinicians should follow at the upcoming meeting, emphasizing collaboration, trial data, and clinical relevance. [WATCH TIME: 3 minutes]

Neurology News Network. for the week ending May 10, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 16, 2025.

A pair of committee chairs for the Peripheral Nerve Society’s Annual Meeting discussed how this year’s meeting reflects a growing emphasis on therapeutic research and translational progress in peripheral neuropathies. [WATCH TIME: 2 minutes]

Verdiperstat showed no significant impact on ALS progression in a recent trial, highlighting the challenges of developing effective treatments for this disease.

The research portfolio director at the Muscular Dystrophy Association discussed the evolving ALS therapeutic landscape, highlighting advances in genetic and RNA-based interventions. [WATCH TIME: 6 minutes]

Seif Elbualy, MD, discusses his role at the Brain and Spine Symposium and shares insights on the future of interventional pain management, evolving techniques, and pharmaceutical innovation.

Priya Kishnani, MD, division chief of Medical Genetics at Duke University, reflects on Pompe disease’s historical and scientific evolution, from early enzyme therapy to next-generation treatment strategies and newborn screening breakthroughs.

New data from the HELIOS trial shows AMX0035 improves glycemic control and stabilizes symptoms in Wolfram syndrome, paving the way for future studies.

Committee chairs Vincent Timmerman, PhD, MSc, and Kathrin Doppler, MD, provide a preview of the 2025 PNS Annual Meeting, giving clinicians an inside look at what to expect from the upcoming conference.

The chief executive officer and founder at CureDuchenne shared her emotional journey from her son’s diagnosis of Duchenne to embracing a new path focused on advocacy, adaptation, and resilience. [WATCH TIME: 4 minutes]

Phase 1b data show oral microbiome therapy MaaT033 slows ALS progression and is well tolerated, supporting future phase 2 development efforts.

This closing episode looks ahead to the future of SMA care, examining how updated best practices aim to accelerate access, optimize outcomes, and fuel ongoing progress.

Here's some of what is coming soon to NeurologyLive® this week.

This episode tackles how proactive, interdisciplinary care and dedicated coordination models are transforming the delivery of SMA treatment across clinical settings.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on B-cell depleting medications for MS.

Panelists comment on how treatment decisions for adolescents and adults with SMA are shaped by lifestyle, quality of life, logistical realities, and access to care.

Neurology News Network. for the week ending May 10, 2025. [WATCH TIME: 4 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of April 2025, compiled all into one place by the NeurologyLive® team.

A study involving 20 patients with ALS found that longitudinal muscle MRI detected progressive atrophy and correlated with muscle strength loss, supporting its potential as a biomarker for ALS progression and clinical trials.